Atezolizumab-induced Encephalitis in a Patient with Hepatocellular Carcinoma: A Case Report and Literature Review

Tomoyuki Satake, Yuta Maruki, Yuko Kubo, Masamichi Takahashi, Akihiro Ohba, Yoshikuni Nagashio, Shunsuke Kondo, Susumu Hijioka, Chigusa Morizane, Hideki Ueno, and Takuji Okusaka

Abstract:

We herein report a case of encephalitis in a 42-year-old woman with hepatocellular carcinoma following atezolizumab plus bevacizumab therapy. After two weeks of treatment, she was admitted for a high fever, impaired consciousness, and convulsive seizure refractory to diazepam. Magnetic resonance imaging revealed a hyperintense splenial lesion. A cerebrospinal fluid test excluded malignancy and infection. These findings were highly suggestive of a diagnosis of encephalitis due to atezolizumab, an immune-related adverse event. Steroid pulse therapy improved the fever and seizure. However, her incomplete right-sided paralysis and aphasia persisted. This is the first case report of encephalitis caused by atezolizumab plus bevacizumab therapy for hepatocellular carcinoma.

Key words: hepatocellular carcinoma, immune-related adverse events, encephalitis, atezolizumab plus bevacizumab, mild encephalitis/encephalopathy with a reversible splenial lesion

Introduction

Over the last decade, immune checkpoint inhibitors (ICIs) have become novel immunotherapeutic agents for the treatment of various cancers. ICIs [e.g. anti-programmed death-1 (PD1), anti-programmed death ligand-1 (PD-L1), and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4)] can induce tumor cell death by activating T cells and inhibiting tumor-induced immunosuppression. However, immune-related adverse events (irAEs) related to ICIs have been reported.

Although irAEs may involve any organ, the skin, colon, endocrine organs, liver, and lungs are most commonly affected. Neurologic irAEs have been reported in 4.2% of patients, manifesting with a wide variety of clinical presentations (1). Neurologic irAEs can be classified as peripheral (e.g., Guillain-Barre syndrome, myasthenia gravis) or central (e.g., encephalitis, aseptic meningitis, and myelitis). Among central irAEs, encephalitis is considered a rare and sometimes insidious but potentially fatal adverse effect (2, 3).

Atezolizumab is a PD-L1 inhibitor approved for the treatment of non-small-cell lung cancer (NSCLC) (4, 5), small-cell lung cancer, advanced triple-negative breast cancer, and advanced hepatocellular carcinoma (HCC). Although the incidence of irAEs caused by atezolizumab is lower than that of other ICIs (6), several serious cases of encephalitis have been reported following atezolizumab therapy (2, 3, 7, 8).

We herein report a case of encephalitis in a patient with HCC following treatment with atezolizumab plus bevacizumab.
Case Report

A 42-year-old woman with chronic hepatitis B caused by mother-to-child transmission was diagnosed in May 2020 with unresectable HCC. Computed tomography (CT) at the diagnosis showed multiple hepatic tumors with portal vein obstruction. Tumor marker tests revealed elevated levels of α-fetoprotein (AFP) (276,700 ng/mL) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) (16,124 mAU/mL). Combination therapy with oral lenvatinib (12 mg/body) and hepatic arterial infusion of cisplatin was initiated. However, after six months, hepatic tumors showed progressive disease. As such, atezolizumab and bevacizumab were given as second-line therapy. Blood tests revealed well-compensated liver disease (Child-Pugh class A) with an albumin-bilirubin grade of 2A in the absence of any history of hepatic encephalopathy.

However, after 12 days of atezolizumab plus bevacizumab therapy, the patient presented with a high fever without any signs of bacterial infection. Antipyretic therapy failed to improve her fever, which persisted for four days with signs of very mild peripheral sensory neuropathy. Rapid influenza diagnostic tests and reverse transcription-polymerase chain reaction for severe acute respiratory syndrome coronavirus 2 were negative. On the 17th day of ICI therapy, she presented to the emergency room for acute-onset impaired consciousness (Glasgow Coma Scale E4V3M5) and a high fever (up to 40°C). A neurologic examination revealed no signs of nuchal rigidity. She then presented with convulsive seizures refractory to diazepam, which prompted admission to the intensive-care unit for airway protection via intubation. Treatment with propofol improved her status epilepticus.

Magnetic resonance imaging (MRI) showed a hyperintense lesion in the splenium of the corpus callosum on T2-weighted imaging (T2WI), fluid-attenuated inversion recovery (FLAIR) imaging, and diffusion-weighted imaging (DWI) (Figure A). These findings were considered to be consistent with the clinicoradiologic diagnosis of mild encephalitis/encephalopathy with a reversible splenial lesion (MERS). In addition, DWI also revealed extensive hyperintense signals along the left cerebral cortex. These hyperintense signals were distributed along the left cerebral cortex regardless of vascular territory, and magnetic resonance angiography showed no abnormal findings and vascular occlusion.
We have described a case of encephalitis following atezolizumab plus bevacizumab therapy in a patient with HCC. To our knowledge, this is the first case report of encephalitis caused by atezolizumab plus bevacizumab therapy for HCC, although it is a known adverse event listed on the package insert. In our case, high-dose steroid therapy with tapering (i.e., 1,000 mg methylprednisolone for 3 days) was an effective treatment for encephalitis. However, the patient’s paralysis and aphasia persisted.

Neurologic irAEs are rare complications of ICI therapy, with an overall incidence ranging from 2% to 4%. Among these cases, grade 3-4 toxicities are uncommon (<1%) (9). A literature review of 59 clinical trials involving 9,208 cancer patients showed the following incidence of neurologic irAEs based on ICI therapy: anti-CTLA4 (3.8%), anti-PD1 (6.1%), and combined anti-PD1 and anti-CTLA4 (12%) (10). Furthermore, although neurologic irAEs may present at any time, the median time to the onset was six weeks after the initiation of ICIs (10).

To our knowledge, only four cases of encephalitis following atezolizumab therapy have been reported (7, 8, 11, 12). Table 2 shows the characteristics and differences among these cases, including our case. In Phases I and II of the POPLAR trial, encephalitis was not reported among NSCLC patients treated with atezolizumab. In contrast, the OAK phase III randomized controlled trial reported that 5 of the 609 (0.8%) patients with NSCLC developed encephalitis following atezolizumab therapy (4). In addition, the IMPower 150 trial, a randomized phase III study, reported one case of posterior reversible encephalopathy syndrome in a patient who received atezolizumab (5). These patients presented with a fever and impaired consciousness about two weeks nately, her seizure and fever disappeared on the third and fifth day of intensive care admission, respectively. A follow-up CSF test performed on the fifth day demonstrated a decrease in the white blood cell count to 43 cells/μL. Due to these improvements, the patient was extubated.

At that time, a neurologic examination showed right-sided paralysis, right hemispatial neglect, and aphasia. On the 12th day of intensive care admission, MRI demonstrated the disappearance of the hyperintense signal in the splenium of the corpus callosum on T2WI, FLAIR, and DWI (Figure B). However, the extensive hyperintense signal along the left cerebral cortex persisted (Figure B). Furthermore, although her hemispatial neglect had improved, her incomplete right-sided paralysis and aphasia persisted despite continued rehabilitation. On the 45th day of hospitalization, the patient was discharged with remaining paralysis and aphasia.

One month after discharge, the patient was readmitted. Blood tests and CT demonstrated elevated liver enzymes, generalized edema, and ascites caused by tumor progression. Unfortunately, the patient died 109 days after the initiation of atezolizumab plus bevacizumab therapy.

### Discussion

| Table 1. Laboratory Data of the Patient on the First Day of Intensive Care Admission. |
|-----------------------------------------------|-------------------------------|
| TP   | 5.7 (g/dL) | WBC | 2100 (μL/L) |
| ALB  | 2.6 (g/dL) | HGB | 9.1 (g/dL)  |
| GLU  | 151 (mg/dL)| PLT | 7.1 (10³/μL) |
| T-Bil| 0.3 (mg/dL)|    |             |
| GOT  | 116 (U/L)  | PT-INR | 1.07         |
| GPT  | 35 (U/L)   | APTT | 28.9 (s)    |
| LDH  | 385 (U/L)  | D-dimer | 3.8 (μg/mL) |
| ALP  | 50 (U/L)   |    |             |
| γ-GTP| 54 (U/L)   | β-D-glucan | <6.0 (μg/mL) |
| CK   | 2,627 (U/L)|    |             |
| CRP  | 1.99 (mg/dL)| TSH | 3.04 (μIU/mL) |
| BUN  | 22 (mg/dL) | FT4 | 1.13 (ng/dL) |
| CRE  | 0.86 (mg/dL)| FT3 | 2.16 (μg/mL) |
| Na   | 141 mmol/L | ACTH | 9.3 (μg/mL) |
| K    | 3.6 mmol/L | Cortisol | 37.8 (μg/dL) |
| Cl   | 109 mmol/L |    |             |
| Ca   | 7.6 (mg/dL)|    |             |
| Mg   | 2.3 (mg/dL)|    |             |

TP: total protein, ALB: albumin, GLU: glucose, T-Bil: total bilirubin, GOT: glutamic oxaloacetic transaminase, GPT: glutamic pyruvic transaminase, LDH: lactate dehydrogenase, ALP: alkaline phosphatase, γ-GTP: γ-glutamyl transpeptidase, CK: creatinine kinase, CRP: C-reactive protein, BUN: blood urea nitrogen, CRE: creatinine, WBC: white blood cell, HGB: hemoglobin, PLT: platelet, PT-INR: prothrombin time, TSH: thyroid-stimulating hormone, FT4: free thyroxine, T3: free triiodothyronine, ACTH: adrenocorticotropic hormone.
after treatment with atezolizumab, suggesting that they might be initial clues for ICI-induced encephalitis. Interestingly, four out of the five encephalitis cases in the OAK trial occurred in Japanese patients. Based on the post-marketing investigations published by pharmaceutical companies in Japan, the frequency of grade >3 encephalitis caused by atezolizumab-based treatment (including both monotherapy and combination therapy) was reported to be 0% in advanced triple-negative breast cancer patients, 0.47% in NSCLC patients, and 0.10% in HCC patients, including our case. The difference in frequencies among individuals and races may be ascribed to a particular immunogenetic background. According to a Korean report, HLA-B*27:05 might ground. According to a case series and literature search, 25% antibodies could be detected in 13 of 25 (52%) patients with ICI-associated encephalitis (16). The presence of paraneoplastic antibodies may increase the risk of developing ICI-associated encephalitis (17). Regarding MRI, typical imaging findings of paraneoplastic limbic encephalitis include T2 hyperintensity and swelling of the mesial temporal lobes (14). In general, MERS patients present with neurologic symptoms (e.g., impaired consciousness or seizures). However, most patients recover within a month, irrespective of treatment. Although the exact pathogenesis of MERS is still not fully understood, viral infections, epilepsy, autoimmune disorders, and malignancy are implicated.

Table 2. Characteristics of Previously Reported Cases of Encephalitis Following Atezolizumab Therapy.

| Sex | Age (years) | Disease | ICI treatment | Onset of symptoms | Symptoms | Cerebrospinal fluid | MRI findings | Treatment | Outcome | Our case |
|-----|-------------|---------|---------------|------------------|----------|---------------------|-------------|-----------|---------|----------|
| Man | 78          | Metastatic lung adenocarcinoma | Atezolizumab | NA                | Disturbance of consciousness, pyrexia | High cell count | Normal | Steroid pulse | Recovery | Man |
| Man | 56          | Metastatic lung adenocarcinoma | Atezolizumab with carboplatin plus nab-paclitaxel | Day17 | Disturbance of consciousness, pyrexia | Elevated protein levels and IL-6 | Normal | Steroid pulse | Recovery | Man |
| Woman | 53          | Metastatic cervical squamous cell carcinoma | Atezolizumab plus bevacizumab | Day13 | Headache, meningeal signs | Elevated protein levels | Normal | High-dose steroids | Recovery | Woman |
| Woman | 59          | Metastatic bladder cancer | Atezolizumab | Day21 | Disturbance of consciousness, pyrexia | Diffuse leptomeningeal enhancement | Normal | Steroid pulse with ventilator | Recovery | Woman |
| Woman | 42          | Hepatocellular carcinoma | Atezolizumab plus bevacizumab | Day12 | Disturbance of consciousness, pyrexia, convulsion | Elevated protein levels | MERS | Steroid pulse with ventilator | Recovery with after effect | Woman |

ICI: immune checkpoint inhibitor, NA: not available, IL-6: interleukin-6, MRI: magnetic resonance imaging, MERS: mild encephalitis/encephalopathy with a reversible splenial lesion
As ICIs become more widely used for the treatment of various cancers, it is important to consider the possibility of encephalitis among patients treated with ICIs. Further investigations are necessary to develop effective diagnostic methods and therapies for the timely diagnosis and management of ICI-related encephalitis.

The authors state that they have no Conflict of Interest (COI).

References

1. Kao JC, Liao B, Markovic SN, et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 74: 1216-1222, 2017.
2. Kim A, Keam B, Cheun H, et al. Immune-checkpoint-inhibitor-induced severe autoimmune encephalitis treated by steroid and intravenous immunoglobulin. J Clin Neurol 15: 259-261, 2019.
3. Williams TJ, Benavides DR, Patrice KA, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 73: 928-933, 2016.
4. Rittmeyer A, Barlesi F, Waterkamp D, et al.; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multi-centre randomised controlled trial. Lancet 389: 255-265, 2017.
5. Socinski MA, Jotte RM, Patrice KA, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 73: 928-933, 2016.
6. Rittmeyer A, Barlesi F, Waterkamp D, et al.; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multi-centre randomised controlled trial. Lancet 389: 255-265, 2017.
7. Levine JJ, Somer RA, Hosoya H, et al. Atezolizumab-induced encephalitis in metastatic bladder cancer: a case report and review of the literature. Clin Genitourin Cancer 15: e847-e849, 2017.
8. Laserna A, Tummala S, Patel N, et al. Atezolizumab-related encephalitis in the intensive care unit: case report and review of the literature. SAGE Open Med 6: 2050313X18792422, 2018.
9. Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system. Ther Adv Neurol Disord 11: 1756286418799864, 2018.
10. Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with combination checkpoint inhibitors: review of the literature. Eur J Cancer 73: 1-8, 2017.
11. Arakawa M, Yamazaki M, Toda Y, et al. Atezolizumab-induced encephalitis in metastatic lung cancer: a case report and literature review. eNeurologicalSci 14: 49-50, 2019.
12. Yamaguchi Y, Nagasawa H, Katagiri Y, et al. Atezolizumab-associated encephalitis in metastatic lung adenocarcinoma: a case report. J Med Case Rep 14: 88, 2020.
13. Chang H, Shin YW, Keam B, et al. HLA-B27 association of autoimmune encephalitis induced by PD-L1 inhibitor. Ann Clin Transl Neurol 7: 2243-2250, 2020.
14. Tada H, Takanashi J, Barkovich AJ, et al. Clinically mild encephalitis/encephalopathy with a reversible splenial lesion. Neurology 63: 1854-1858, 2004.
15. Conry RM, Sullivan JC, Nabors LB 3rd. Ipilimumab-induced encephalopathy with a reversible splenial lesion. Cancer Immunol Res 3: 598-601, 2015.
16. Stuby J, Herren T, Schweiger Naumberger G, et al. Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature. Swiss Med Wkly 150: w20377, 2020.
17. Gill A, Perez MA, Perrone CM, et al. A case series of PD-L1 inhibitor-associated paraneoplastic neurologic syndromes. J Neuroimmunol 334: 576980, 2019.
18. Madhavan AA, Carr CM, Morris PP, et al. Imaging review of paraneoplastic neurologic syndromes. AJNR Am J Neuroradiol 41: 2176-2187, 2020.
19. Choe PE, Ong WC, Lui HF, et al. Epidemiology and prognosis of paraneoplastic syndromes in hepatocellular carcinoma. ISRN Oncol 2013: 684026, 2013.
20. Matsui T, Hori Y, Nagano H, et al. Poorly differentiated hepatocellular carcinoma accompanied by anti-Hu antibody-positive paraneoplastic peripheral neuropathy. Pathol Int 65: 388-392, 2015.
21. Graus F, Vogrig A, Muñiz-Castrillo S, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurourol Urodyn 30: e1014, 2021.